Slide 1: Third Quarter 2024 Earnings Presentation
AngioDynamics Third Quarter 2024 Earnings Presentation April 4, 2024
Slide 2: Forward-Looking Statement
AngioDynamics First Quarter 2024 Earnings Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future fi
Slide 3: Corporate Developments – Pro forma Q3 and YTD FY24
IDE Clinical Studies and Pathway Expansion Corporate Developments – Pro forma Q3 and YTD FY24 (please see next slide for GAAP results) AngioDynamics Third Quarter 2024 Earnings 3 Initiated restructuring of manufacturing footprint to a fully outsourced model Divested the PICCs and Midlines businesses
Slide 4: Q3 FY24 Results (unaudited)
Q3 FY24 Results (unaudited) AngioDynamics Third Quarter 2024 Earnings 4 $ in thousands (except per share data) Q3 FY24 As Reported Q3 FY23 As Reported Change Q3 FY24 Pro Forma* Q3 FY23 Pro Forma* Change Revenue $75,182 $80,712 (6.9%) $65,971 $61,090 8.0% Med Tech Med Device $25,844 $49,338 $22,874 $
Slide 5: YTD FY24 Results (unaudited)
YTD FY24 Results (unaudited) AngioDynamics Third Quarter 2024 Earnings 5 $ in thousands (except per share data) YTD FY24 As Reported YTD FY23 As Reported Change YTD FY24 Pro Forma* YTD FY23 Pro Forma* Change Revenue $232,934 $247,678 (6.0%) $199,598 $187,418 6.5% Med Tech Med Device $77,068 $155,866
Slide 6: Q3 and YTD FY24 Results (pro forma)
Q3 and YTD FY24 Results (pro forma*) 6 Med Device Med Tech 12.6% growth 5.2% growth Q3 Revenue Growth Q3 FY23 Q3 FY24 Q3 Revenue Contribution Q3 FY23 Q3 FY24 Med Tech Gross Margin 61.5% Med Device Gross Margin 44.4% AngioDynamics Third Quarter 2024 Earnings Med Device Med Tech 9.6% growth 4.6% growt
Slide 7: Sales Comparison to Prior-Year Period
Sales Comparison to Prior-Year Period AngioDynamics Third Quarter 2024 Earnings 7 Med Tech Q3FY24 YTD FY24 Auryon 14.7% 17.4% Thrombus Management* AngioVac AlphaVac (6.5%) 0.2% (43.8%) (6.6%) (6.3%) (10.5%) NanoKnife® Disposables 19.8% 15.1% NanoKnife® Capital 230.9% 68.6% Med Device Q3 FY24 YTD FY2
Slide 8: FY24 Updated Guidance
FY24 Updated Guidance 8 * FY23 pro forma results excluding the divested and discontinued assets were $257.2 million for revenue, 54.9% for gross margin and adjusted loss per share of $0.55. AngioDynamics Third Quarter 2024 Earnings Guidance* Updated Guidance* Revenue $328 - $333 million $270 - $275
Slide 9: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 10: Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
10 (in thousands, except per share data) (in thousands, except per share data) Reconciliation of GAAP to Non-GAAP Pro Forma Results for the Consolidated Income Statements
Slide 11: Reconciliation of GAAP to Non-GAAP Adjusted Net Loss and EPS
Reconciliation of GAAP to Non-GAAP Adjusted Net Loss and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. The total value
Slide 12: Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss and EPS
Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma Net Loss and EPS Reconciliation of Non-GAAP Pro Forma Net Loss to Adjusted Pro Forma EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs,
Slide 13: Detail of Acquisition, Restructuring and Other Items, net
13 Detail of “Acquisition, Restructuring and Other Items, net”
Slide 14: Reconciliation of Pro Forma Sales and Gross Margin by Product Category
14 (in thousands) Reconciliation of GAAP to Non-GAAP Pro Forma Results for Sales and Gross Margin by Product Category (in thousands)
Slide 15: Thank You
Thank You AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate, or a subsidiary. All other trademarks are property of their respective owners. © 2023 AngioDynamics, Inc.